Odycin (Clarithromycin)

Clarithromycin, the active ingredient in Odycin, is a macrolide antibiotic presented as an oral tablet for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial bronchitis, skin and soft‑tissue infections, and is used as part of Helicobacter pylori eradication regimens in adults.

GNH USA supplies Odycin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory tract, skin and gastrointestinal system.

- Community‑acquired pneumonia: eradicates the causative bacteria, improving respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms. - Skin and soft‑tissue infections: clears bacterial pathogens, promoting wound healing. - Helicobacter pylori eradication: contributes to bacterial clearance when combined with other agents in a multi‑drug regimen.

Clarithromycin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT interval prolongation: may predispose to cardiac arrhythmias. - Clostridioides difficile infection: severe colitis. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe arrhythmias: especially in patients with pre‑existing cardiac conditions. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

Before prescribing Clarithromycin, clinicians should consider several safety measures.

- Liver function assessment: monitor hepatic enzymes in patients with liver disease. - Cardiac monitoring: avoid in patients with known QT prolongation or electrolyte disturbances. - Allergy check: do not use in individuals with a documented macrolide hypersensitivity. - Renal impairment: dose adjustment may be required for severe renal dysfunction. - Drug interaction vigilance: review concomitant medications that affect QT interval or CYP3A4 metabolism. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Clarithromycin interacts with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Cisapride: risk of serious cardiac arrhythmias. - Pimozide: may cause QT prolongation and torsades de pointes. - Ergot alkaloids: increased risk of ergotism. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): can raise clarithromycin levels dramatically.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Statins (simvastatin, lovastatin): increased risk of myopathy. - Digoxin: potential increase in serum concentrations. - Oral contraceptives: possible reduction in efficacy, advise alternative contraception.